SCHEMBL3908352

SCHEMBL3908352

O=c1[nH]n(Cc2ccccc2Cl)c2cc(Cl)c(NS(=O)(=O)c3ccc(Cl)cc3)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
TP53 P04637 2/20 0.42
GAA P10253 1/20 0.41
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
KDR P35968 1/20 0.41
ALDH1A1 P00352 1/20 0.40
BRD4 O60885 2/20 0.40
DRD2 P14416 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
DRD3 P35462 1/20 0.40
HTR6 P50406 1/20 0.40
HKDC1 Q2TB90 1/20 0.40
CCR2 P41597 2/20 0.39
TRIM24 O15164 1/20 0.39
BRD1 O95696 1/20 0.39
BRPF1 P55201 1/20 0.39
ERBB2 P04626 1/20 0.39
HSP90AA1 P07900 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3907931 0.86 ACLY (0.43) MAPTTP53CCR2
SCHEMBL3904617 0.86 CCR2 (0.46) MAPTCCR2PGAM1
SCHEMBL1813077 0.84 PTGES2 (0.45) BRD4CCR4
SCHEMBL1822618 0.80 MEN1 (0.47) MAPTTP53GAAFLT1FLT4
SCHEMBL3917135 0.79 PGR (0.48) BRD4CCR2CCR1CCR4
SCHEMBL3917122 0.78 NR1I2 (0.45) ALDH1A1BRD4
SCHEMBL1811314 0.77 TRPV4 (0.45) MAPTGAACCR2KMT2A
SCHEMBL1827084 0.76 CCR9 (0.49) MAPTTP53CCR2PGAM1
SCHEMBL3906458 0.76 ACLY (0.47) CCR2
SCHEMBL3906370 0.75 PGAM1 (0.47) MAPTTP53CCR2PGAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors HSD17B1, HSD11B1, HSD17B7 MAPT 2996/4885TP53 4361/4885GAA 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.